Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета
Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета
Насонов Е.Л., Решетняк Т.М., Алекберова З.С. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020; 92 (5): 4–14. DOI: 10.26442/00403660.2020.05.000697
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Неконтролируемые гиперкоагуляция и воспаление («тромбовоспаление» – thromboinflammation), представляющие собой независимые, но тесно связанные и амплифицирующие друг друга патологические процессы, составляют основу патогенеза широкого спектра заболеваний и осложнений, в том числе при иммуновоспалительных (аутоиммунных) ревматических заболеваниях, с развитием потенциально смертельных повреждений внутренних органов. Одним из ярких прототипов «тромбовоспалительных» патологических состояний является тромботическая микроангиопатия. Существование тесной взаимосвязи между факторами внешней среды, генетическими дефектами свертывания крови и компонентов комплемента, воспалением и аутоиммунитетом в качестве патогенетических механизмов микротромбоза привлекает особое внимание к изучению тромботической микроангиопатии при иммуновоспалительных ревматических заболеваниях, в первую очередь системной красной волчанке, антифосфолипидном синдроме и склеродермическом почечном кризе. Эти исследования в перспективе могут иметь значение для расширения представлений о роли аутоиммунных механизмов патогенеза «критических» нарушений гемостаза при заболеваниях человека, разработки новых подходов к терапии. В последнее время привлечено внимание к применению для лечения системной красной волчанки и антифосфолипидного синдрома препарата экулизумаб, представляющего собой гуманизированные моноклональные IgG2/4k-антитела, блокирующие С5а-компонент комплемента и образование мембраноатакующего комплекса (С5b-9). Препарат зарегистрирован для лечения атипичного гемолитико-уремического синдрома, пароксизмальной ночной гемоглобинурии, а также тяжелых форм миастении и оптического нейромиелита. Дальнейшие исследования в этом направлении создадут предпосылки для улучшения прогноза не только у пациентов с орфанной патологией, но и широко распространенными заболеваниями человека.
Ключевые слова: тромботическая микроангиопатия, системная красная волчанка, антифосфолипидный синдром, экулизумаб.
Keywords: thrombotic microangiopathy, systemic lupus erythematosus, antiphospholipid syndrome, eculizumab.
Ключевые слова: тромботическая микроангиопатия, системная красная волчанка, антифосфолипидный синдром, экулизумаб.
________________________________________________
Keywords: thrombotic microangiopathy, systemic lupus erythematosus, antiphospholipid syndrome, eculizumab.
Список литературы
1. Herwald H, Theopold U. Hemostasis in invertebrates and vertebrates: an evolutionary excursion. J Innate Immun. 2011;3(1):1-2. doi: 10.1159/000322064
2. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-18. doi: 10.1182/blood-2018-11-882993
3. Chanchal S, Mishra A, Singh MK, Ashraf MZ. Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes. Front Cell Dev Biol. 2020;8:73. doi: 10.3389/fcell.2020.00073
4. Margetic S. Inflammation and haemostasis. Biochem Med. 2012;22:49-62. doi: 10.11613/BM.2012.006
5. Babar F, Cohen SD. Thrombotic Microangiopathies with Rheumatologic Involvement. Rheum Dis Clin North Am. 2018 Nov;44(4):635-49. doi: 10.1016/j.rdc.2018.06.010
6. George JN, Nester CM. Syndromes of thrombotic microangiopathy.
N Engl J Med. 2014;371:654-66. doi:10.1056/NEJMoa1410490
7. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010
8. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17. doi: 10.2215/CJN.00620117
9. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-7. doi: 10.1093/ckj/sfz040
10. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. doi: 10.1111/1744-9987.12763
11. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;38:817-24. doi: 10.1016/S0140-6736(17)30062-4
12. Plautz WE, Raval JS, Dyer MR, et al. ADAMTS13: origins, applications, and prospects. Transfusion. 2018;58(10):2453-62. doi: 10.1111/trf.14804
13. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol. 2019;10:337. doi: 10.3389/fimmu.2019.00337
14. Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-86. doi: 10.1053/j.ackd.2019.08.012
15. Chaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019;10:449. doi: 10.3389/fimmu.2019.00449
16. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018;17(9):882-9. doi: 10.1016/
j.autrev.2018.03.012
17. Allanore Y, Distler O, Matucci-Cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol. 2018;70(2):162-70. doi: 10.1002/art.40377
18. Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-47. doi: 10.1038/nrrheum.2017.125
19. Goldberg BS, Ackerman ME. Antibody-mediated complement activation in pathology and protection. Immunol Cell Biol. 2020 Mar 6. doi: 10.1111/imcb.12324
20. Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. doi: 10.1016/j.smim.2019.101339
21. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune
Disease. Front Immunol. 2019;10:672. doi: 10.3389/fimmu.2019.
00672
22. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
23. Насонов Е.Л. Системная красная волчанка. В кн.: Российские клинические рекомендации. 2017. М.: ГЭОТАР-Медиа, 2017; с. 113-41 [Nasonov EL. Systemic lupus erythematosus. In: Russian Kliscientific recommendations. 2017. Moscow: GEOTAR-Media, 2017; p. 113-41 (In Russ.)].
24. Couture P, Hie M, Pineton de Chambrun M, et al. FRI0302 Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort. Ann Rheum Dis. 2018;77:688-9.
25. Yue C, Su J, Gao R, et al. Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. J Rheumatol. 2018;45(11):1549-56. doi: 10.3899/jrheum.170811
26. Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005
27. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992;19:1474-8. PMid: 1433020.
28. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991;18:1916-8. PMid: 1795331.
29. Tulai IM, Penciu OM, Raut R, Rudinskaya A. Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. Tex Heart Inst J. 2019;46(1):48-52. doi: 10.14503/THIJ-17-6472
30. Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279-89.
doi: 10.1038/nrneph.2014.38
31. Tsuchimoto A, Matsukuma Y, Ueki K, et al. Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia. CEN Case Rep. 2019;8(1):1-7.
doi: 10.1007/s13730-018-0354-x
32. Zhou XJ, Chen M, Wang SX, et al. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report. Lupus. 2017;26(7):777-82.
doi: 10.1177/0961203316682098
33. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-6. doi: 10.1136/ard.2003.007245
34. Asherson RA, Pierangel SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429-33.
doi: 10.1136/ard.2006.067033
35. Myakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306.
doi: 10.1111/j.1538-7836.2006.01753.x
36. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
doi: 10.1002/art.10187
37. Решетняк Т.М., Алекберова З.С., Александрова Е.Н. и др. Клинические аспекты антифосфолипидного синдрома. Вестн. РАМН. 2003;7:31-4 [Reshetnyak TM, Alekberova ZS, Alexandrova EN, et al. Clinic-clinical aspects of antiphospholipid syndrome. Vestn. RAMS. 2003;7:31-4 (In Russ.)].
38. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004 [Nasonov EL. Antifosfolipidnyi sindrom. Moscow: Litterra, 2004 (In Russ.)].
39. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010-21. doi: 10.1056/
NEJMra1705454
40. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-4. doi: 10.1182/bloodadvances.2018019596
41. Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Ren Fail. 2019;42(1):19-29. doi: 10.1080/0886022X.2019.1702057
42. Ono M, Ohashi N, Namikawa A, et al. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Intern Med. 2018;57(11):1617-23. doi: 10.2169/internalmedicine.0228-17
43. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-95. doi: 10.1038/nrneph.2017.85
44. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142
45. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005
46. Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007
47. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213
48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П. и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov ЕL, Beketova TV, Ananyeva LP, et al. Prospects for anti-b-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi: 10.14412/1995-4484-2019-3-40
49. Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004
50. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793
51. Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012
52. Diószegi Á, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-8. doi: 10.1177/0961203318768890
53. Bhat SP, Rahman SZ. Rituximab treatment in new and refractory thrombotic thrombocytopenic purpura (TTP) patients: a review. IJMSCR. 2016;2:1-6.
54. Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512-8. doi: 10.1182/bloodadvances
55. Coppo P. Cuker A, George JN. Thrombotic thrombocytopenic purputa: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3:26-37. doi: 10.1002/rth2.12160
56. Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019;58(7):859-74. doi: 10.1007/s40262-019-00742-8
57. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25-40. doi: 10.3904/kjim.201
58. Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648. doi: 10.1016/j.jns.2019.11
59. Patel A, Lynch F, Shepherd SA. Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Curr Treat Options Neurol. 2020;22(3):7. doi: 10.1007/s11940-020-0616-8
60. Tinti MG, Carnevale V, Inglese M, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-8. doi: 10.1007/s10238-019-00565-8
61. De Holanda MI, Pôrto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36(12):2859-67. doi: 10.1007/s10067-017-3823-2
62. Raufi AG, Scott S, Darwish O, et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep. 2016;8(3):6625. eCollection 2016 Sep 28.
63. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2014;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031
64. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286-8. doi: 10.1093/rheumatology/kev307
65. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719-23. doi: 10.1002/art.34440
66. Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517-23. doi: 10.1016/j.semarthrit.2011.05.007
67. Muller-Calleja N, Ritter S, Hollerbach A, et al. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018;2:979-86. doi: 10.1182/bloodadvances.2018017095
68. Strakhan M, Hurtado-Sbordoni M, Galeas N, et al. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371. doi: 10.1155/2014/704371
69. Wig S, Chan M, Thachil J, et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382-4. doi: 10.1093/rheumatology/kev371
70. Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report. Medicine. 2017;96:e6338. doi: 10.1097/MD.0000000000006338
71. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost. 2016;14:675-84. doi: 10.1111/jth.13257
72. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143. doi: 10.1097/MD.0000000000000143
73. Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337-9. doi: 10.1093/rheumatology/kew040
74. Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome – a case report and literature review. Rheumatology. 2018;57:2055-7. doi: 10.1093/rheumatology/key2
75. Geethakumari PR, Mille P, Gulati R, Nagalla S. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci. 2017;56(3):400-3. doi: 10.1016/j.transci.2017.02.007
76. Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. Clin Rheumatol. 2015;21(6):311-3. doi: 10.1097/RHU.0000000000000290
77. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14(2):459-65. doi: 10.1111/ajt.12540
78. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744-5. doi: 10.1056/NEJMc0910965
79. Bakhtar O, Thajudeen B, Braunhut BL, et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation. 2014;98(3):e17-8. doi: 10.1097/TP.0000000000000267
80. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13(8):2179-85. doi: 10.1111/ajt.12319
81. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x
82. Olson SR, Lu E, Sulpizio E, et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033
83. Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341-52. doi: 10.1016/j.molimm.2019.07.030
84. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019 Apr 3;10:672. doi: 10.3389/fimmu.2019.00672
85. Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS One 11:e0164646. doi: 10.1371/journal.pone.0164646
86. Jayne DRW, Bruchfeld AN, Harper L, et al; CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017;28(9):2756-67. doi: 10.1681/ASN.2016111179
87. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603-10. doi: 10.1182/blood-2012-04-420943
88. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. doi: 10.1177/2040620720902904
2. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-18. doi: 10.1182/blood-2018-11-882993
3. Chanchal S, Mishra A, Singh MK, Ashraf MZ. Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes. Front Cell Dev Biol. 2020;8:73. doi: 10.3389/fcell.2020.00073
4. Margetic S. Inflammation and haemostasis. Biochem Med. 2012;22:49-62. doi: 10.11613/BM.2012.006
5. Babar F, Cohen SD. Thrombotic Microangiopathies with Rheumatologic Involvement. Rheum Dis Clin North Am. 2018 Nov;44(4):635-49. doi: 10.1016/j.rdc.2018.06.010
6. George JN, Nester CM. Syndromes of thrombotic microangiopathy.
N Engl J Med. 2014;371:654-66. doi:10.1056/NEJMoa1410490
7. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010
8. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17. doi: 10.2215/CJN.00620117
9. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-7. doi: 10.1093/ckj/sfz040
10. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. doi: 10.1111/1744-9987.12763
11. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;38:817-24. doi: 10.1016/S0140-6736(17)30062-4
12. Plautz WE, Raval JS, Dyer MR, et al. ADAMTS13: origins, applications, and prospects. Transfusion. 2018;58(10):2453-62. doi: 10.1111/trf.14804
13. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol. 2019;10:337. doi: 10.3389/fimmu.2019.00337
14. Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-86. doi: 10.1053/j.ackd.2019.08.012
15. Chaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019;10:449. doi: 10.3389/fimmu.2019.00449
16. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018;17(9):882-9. doi: 10.1016/
j.autrev.2018.03.012
17. Allanore Y, Distler O, Matucci-Cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol. 2018;70(2):162-70. doi: 10.1002/art.40377
18. Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-47. doi: 10.1038/nrrheum.2017.125
19. Goldberg BS, Ackerman ME. Antibody-mediated complement activation in pathology and protection. Immunol Cell Biol. 2020 Mar 6. doi: 10.1111/imcb.12324
20. Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. doi: 10.1016/j.smim.2019.101339
21. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune
Disease. Front Immunol. 2019;10:672. doi: 10.3389/fimmu.2019.
00672
22. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
23. Насонов Е.Л. Системная красная волчанка. В кн.: Российские клинические рекомендации. 2017. М.: ГЭОТАР-Медиа, 2017; с. 113-41 [Nasonov EL. Systemic lupus erythematosus. In: Russian Kliscientific recommendations. 2017. Moscow: GEOTAR-Media, 2017; p. 113-41 (In Russ.)].
24. Couture P, Hie M, Pineton de Chambrun M, et al. FRI0302 Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort. Ann Rheum Dis. 2018;77:688-9.
25. Yue C, Su J, Gao R, et al. Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. J Rheumatol. 2018;45(11):1549-56. doi: 10.3899/jrheum.170811
26. Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005
27. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992;19:1474-8. PMid: 1433020.
28. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991;18:1916-8. PMid: 1795331.
29. Tulai IM, Penciu OM, Raut R, Rudinskaya A. Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. Tex Heart Inst J. 2019;46(1):48-52. doi: 10.14503/THIJ-17-6472
30. Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279-89.
doi: 10.1038/nrneph.2014.38
31. Tsuchimoto A, Matsukuma Y, Ueki K, et al. Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia. CEN Case Rep. 2019;8(1):1-7.
doi: 10.1007/s13730-018-0354-x
32. Zhou XJ, Chen M, Wang SX, et al. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report. Lupus. 2017;26(7):777-82.
doi: 10.1177/0961203316682098
33. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-6. doi: 10.1136/ard.2003.007245
34. Asherson RA, Pierangel SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429-33.
doi: 10.1136/ard.2006.067033
35. Myakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306.
doi: 10.1111/j.1538-7836.2006.01753.x
36. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
doi: 10.1002/art.10187
37. Решетняк Т.М., Алекберова З.С., Александрова Е.Н. и др. Клинические аспекты антифосфолипидного синдрома. Вестн. РАМН. 2003;7:31-4 [Reshetnyak TM, Alekberova ZS, Alexandrova EN, et al. Clinic-clinical aspects of antiphospholipid syndrome. Vestn. RAMS. 2003;7:31-4 (In Russ.)].
38. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004 [Nasonov EL. Antifosfolipidnyi sindrom. Moscow: Litterra, 2004 (In Russ.)].
39. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010-21. doi: 10.1056/NEJMra1705454
40. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-4. doi: 10.1182/bloodadvances.2018019596
41. Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Ren Fail. 2019;42(1):19-29. doi: 10.1080/0886022X.2019.1702057
42. Ono M, Ohashi N, Namikawa A, et al. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Intern Med. 2018;57(11):1617-23. doi: 10.2169/internalmedicine.0228-17
43. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-95. doi:
10.1038/nrneph.2017.85
44. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142
45. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005
46. Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007
47. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213
48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П. и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov ЕL, Beketova TV, Ananyeva LP, et al. Prospects for anti-b-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi: 10.14412/1995-4484-2019-3-40
49. Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004
50. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793
51. Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012
52. Diószegi Á, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-8. doi: 10.1177/0961203318768890
53. Bhat SP, Rahman SZ. Rituximab treatment in new and refractory thrombotic thrombocytopenic purpura (TTP) patients: a review. IJMSCR. 2016;2:1-6.
54. Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512-8. doi: 10.1182/bloodadvances
55. Coppo P. Cuker A, George JN. Thrombotic thrombocytopenic purputa: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3:26-37. doi: 10.1002/rth2.12160
56. Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019;58(7):859-74. doi: 10.1007/s40262-019-00742-8
57. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25-40. doi: 10.3904/kjim.201
58. Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648. doi: 10.1016/j.jns.2019.11
59. Patel A, Lynch F, Shepherd SA. Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Curr Treat Options Neurol. 2020;22(3):7. doi: 10.1007/s11940-020-0616-8
60. Tinti MG, Carnevale V, Inglese M, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-8. doi: 10.1007/s10238-019-00565-8
61. De Holanda MI, Pôrto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36(12):2859-67. doi: 10.1007/s10067-017-3823-2
62. Raufi AG, Scott S, Darwish O, et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep. 2016;8(3):6625. eCollection 2016 Sep 28.
63. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2014;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031
64. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286-8. doi: 10.1093/rheumatology/kev307
65. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719-23. doi: 10.1002/art.34440
66. Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517-23. doi: 10.1016/j.semarthrit.2011.05.007
67. Muller-Calleja N, Ritter S, Hollerbach A, et al. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018;2:979-86. doi: 10.1182/bloodadvances.2018017095
68. Strakhan M, Hurtado-Sbordoni M, Galeas N, et al. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371. doi: 10.1155/2014/704371
69. Wig S, Chan M, Thachil J, et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382-4. doi: 10.1093/rheumatology/kev371
70. Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report. Medicine. 2017;96:e6338. doi: 10.1097/MD.0000000000006338
71. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost. 2016;14:675-84. doi: 10.1111/jth.13257
72. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143. doi: 10.1097/MD.0000000000000143
73. Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337-9. doi: 10.1093/rheumatology/kew040
74. Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome – a case report and literature review. Rheumatology. 2018;57:2055-7. doi: 10.1093/rheumatology/key2
75. Geethakumari PR, Mille P, Gulati R, Nagalla S. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci. 2017;56(3):400-3. doi: 10.1016/j.transci.2017.02.007
76. Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. Clin Rheumatol. 2015;21(6):311-3. doi: 10.1097/RHU.0000000000000290
77. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14(2):459-65. doi: 10.1111/ajt.12540
78. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744-5. doi: 10.1056/NEJMc0910965
79. Bakhtar O, Thajudeen B, Braunhut BL, et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation. 2014;98(3):e17-8. doi: 10.1097/TP.0000000000000267
80. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13(8):2179-85. doi: 10.1111/ajt.12319
81. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x
82. Olson SR, Lu E, Sulpizio E, et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033
83. Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341-52. doi: 10.1016/j.molimm.2019.07.030
84. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019 Apr 3;10:672. doi: 10.3389/fimmu.2019.00672
85. Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS One 11:e0164646. doi: 10.1371/journal.pone.0164646
86. Jayne DRW, Bruchfeld AN, Harper L, et al; CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017;28(9):2756-67. doi: 10.1681/ASN.2016111179
87. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603-10. doi: 10.1182/blood-2012-04-420943
88. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. doi: 10.1177/2040620720902904
2. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-18. doi: 10.1182/blood-2018-11-882993
3. Chanchal S, Mishra A, Singh MK, Ashraf MZ. Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes. Front Cell Dev Biol. 2020;8:73. doi: 10.3389/fcell.2020.00073
4. Margetic S. Inflammation and haemostasis. Biochem Med. 2012;22:49-62. doi: 10.11613/BM.2012.006
5. Babar F, Cohen SD. Thrombotic Microangiopathies with Rheumatologic Involvement. Rheum Dis Clin North Am. 2018 Nov;44(4):635-49. doi: 10.1016/j.rdc.2018.06.010
6. George JN, Nester CM. Syndromes of thrombotic microangiopathy.
N Engl J Med. 2014;371:654-66. doi:10.1056/NEJMoa1410490
7. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010
8. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17. doi: 10.2215/CJN.00620117
9. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-7. doi: 10.1093/ckj/sfz040
10. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. doi: 10.1111/1744-9987.12763
11. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;38:817-24. doi: 10.1016/S0140-6736(17)30062-4
12. Plautz WE, Raval JS, Dyer MR, et al. ADAMTS13: origins, applications, and prospects. Transfusion. 2018;58(10):2453-62. doi: 10.1111/trf.14804
13. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol. 2019;10:337. doi: 10.3389/fimmu.2019.00337
14. Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-86. doi: 10.1053/j.ackd.2019.08.012
15. Chaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019;10:449. doi: 10.3389/fimmu.2019.00449
16. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018;17(9):882-9. doi: 10.1016/
j.autrev.2018.03.012
17. Allanore Y, Distler O, Matucci-Cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol. 2018;70(2):162-70. doi: 10.1002/art.40377
18. Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-47. doi: 10.1038/nrrheum.2017.125
19. Goldberg BS, Ackerman ME. Antibody-mediated complement activation in pathology and protection. Immunol Cell Biol. 2020 Mar 6. doi: 10.1111/imcb.12324
20. Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. doi: 10.1016/j.smim.2019.101339
21. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune
Disease. Front Immunol. 2019;10:672. doi: 10.3389/fimmu.2019.
00672
22. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
23. Насонов Е.Л. Системная красная волчанка. В кн.: Российские клинические рекомендации. 2017. М.: ГЭОТАР-Медиа, 2017; с. 113-41 [Nasonov EL. Systemic lupus erythematosus. In: Russian Kliscientific recommendations. 2017. Moscow: GEOTAR-Media, 2017; p. 113-41 (In Russ.)].
24. Couture P, Hie M, Pineton de Chambrun M, et al. FRI0302 Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort. Ann Rheum Dis. 2018;77:688-9.
25. Yue C, Su J, Gao R, et al. Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. J Rheumatol. 2018;45(11):1549-56. doi: 10.3899/jrheum.170811
26. Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005
27. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992;19:1474-8. PMid: 1433020.
28. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991;18:1916-8. PMid: 1795331.
29. Tulai IM, Penciu OM, Raut R, Rudinskaya A. Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. Tex Heart Inst J. 2019;46(1):48-52. doi: 10.14503/THIJ-17-6472
30. Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279-89.
doi: 10.1038/nrneph.2014.38
31. Tsuchimoto A, Matsukuma Y, Ueki K, et al. Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia. CEN Case Rep. 2019;8(1):1-7.
doi: 10.1007/s13730-018-0354-x
32. Zhou XJ, Chen M, Wang SX, et al. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report. Lupus. 2017;26(7):777-82.
doi: 10.1177/0961203316682098
33. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-6. doi: 10.1136/ard.2003.007245
34. Asherson RA, Pierangel SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429-33.
doi: 10.1136/ard.2006.067033
35. Myakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306.
doi: 10.1111/j.1538-7836.2006.01753.x
36. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
doi: 10.1002/art.10187
37. Решетняк Т.М., Алекберова З.С., Александрова Е.Н. и др. Клинические аспекты антифосфолипидного синдрома. Вестн. РАМН. 2003;7:31-4 [Reshetnyak TM, Alekberova ZS, Alexandrova EN, et al. Clinic-clinical aspects of antiphospholipid syndrome. Vestn. RAMS. 2003;7:31-4 (In Russ.)].
38. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004 [Nasonov EL. Antifosfolipidnyi sindrom. Moscow: Litterra, 2004 (In Russ.)].
39. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010-21. doi: 10.1056/
NEJMra1705454
40. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-4. doi: 10.1182/bloodadvances.2018019596
41. Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Ren Fail. 2019;42(1):19-29. doi: 10.1080/0886022X.2019.1702057
42. Ono M, Ohashi N, Namikawa A, et al. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Intern Med. 2018;57(11):1617-23. doi: 10.2169/internalmedicine.0228-17
43. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-95. doi: 10.1038/nrneph.2017.85
44. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142
45. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005
46. Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007
47. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213
48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П. и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov ЕL, Beketova TV, Ananyeva LP, et al. Prospects for anti-b-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi: 10.14412/1995-4484-2019-3-40
49. Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004
50. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793
51. Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012
52. Diószegi Á, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-8. doi: 10.1177/0961203318768890
53. Bhat SP, Rahman SZ. Rituximab treatment in new and refractory thrombotic thrombocytopenic purpura (TTP) patients: a review. IJMSCR. 2016;2:1-6.
54. Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512-8. doi: 10.1182/bloodadvances
55. Coppo P. Cuker A, George JN. Thrombotic thrombocytopenic purputa: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3:26-37. doi: 10.1002/rth2.12160
56. Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019;58(7):859-74. doi: 10.1007/s40262-019-00742-8
57. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25-40. doi: 10.3904/kjim.201
58. Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648. doi: 10.1016/j.jns.2019.11
59. Patel A, Lynch F, Shepherd SA. Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Curr Treat Options Neurol. 2020;22(3):7. doi: 10.1007/s11940-020-0616-8
60. Tinti MG, Carnevale V, Inglese M, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-8. doi: 10.1007/s10238-019-00565-8
61. De Holanda MI, Pôrto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36(12):2859-67. doi: 10.1007/s10067-017-3823-2
62. Raufi AG, Scott S, Darwish O, et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep. 2016;8(3):6625. eCollection 2016 Sep 28.
63. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2014;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031
64. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286-8. doi: 10.1093/rheumatology/kev307
65. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719-23. doi: 10.1002/art.34440
66. Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517-23. doi: 10.1016/j.semarthrit.2011.05.007
67. Muller-Calleja N, Ritter S, Hollerbach A, et al. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018;2:979-86. doi: 10.1182/bloodadvances.2018017095
68. Strakhan M, Hurtado-Sbordoni M, Galeas N, et al. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371. doi: 10.1155/2014/704371
69. Wig S, Chan M, Thachil J, et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382-4. doi: 10.1093/rheumatology/kev371
70. Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report. Medicine. 2017;96:e6338. doi: 10.1097/MD.0000000000006338
71. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost. 2016;14:675-84. doi: 10.1111/jth.13257
72. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143. doi: 10.1097/MD.0000000000000143
73. Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337-9. doi: 10.1093/rheumatology/kew040
74. Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome – a case report and literature review. Rheumatology. 2018;57:2055-7. doi: 10.1093/rheumatology/key2
75. Geethakumari PR, Mille P, Gulati R, Nagalla S. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci. 2017;56(3):400-3. doi: 10.1016/j.transci.2017.02.007
76. Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. Clin Rheumatol. 2015;21(6):311-3. doi: 10.1097/RHU.0000000000000290
77. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14(2):459-65. doi: 10.1111/ajt.12540
78. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744-5. doi: 10.1056/NEJMc0910965
79. Bakhtar O, Thajudeen B, Braunhut BL, et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation. 2014;98(3):e17-8. doi: 10.1097/TP.0000000000000267
80. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13(8):2179-85. doi: 10.1111/ajt.12319
81. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x
82. Olson SR, Lu E, Sulpizio E, et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033
83. Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341-52. doi: 10.1016/j.molimm.2019.07.030
84. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019 Apr 3;10:672. doi: 10.3389/fimmu.2019.00672
85. Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS One 11:e0164646. doi: 10.1371/journal.pone.0164646
86. Jayne DRW, Bruchfeld AN, Harper L, et al; CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017;28(9):2756-67. doi: 10.1681/ASN.2016111179
87. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603-10. doi: 10.1182/blood-2012-04-420943
88. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. doi: 10.1177/2040620720902904
________________________________________________
2. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-18. doi: 10.1182/blood-2018-11-882993
3. Chanchal S, Mishra A, Singh MK, Ashraf MZ. Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes. Front Cell Dev Biol. 2020;8:73. doi: 10.3389/fcell.2020.00073
4. Margetic S. Inflammation and haemostasis. Biochem Med. 2012;22:49-62. doi: 10.11613/BM.2012.006
5. Babar F, Cohen SD. Thrombotic Microangiopathies with Rheumatologic Involvement. Rheum Dis Clin North Am. 2018 Nov;44(4):635-49. doi: 10.1016/j.rdc.2018.06.010
6. George JN, Nester CM. Syndromes of thrombotic microangiopathy.
N Engl J Med. 2014;371:654-66. doi:10.1056/NEJMoa1410490
7. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017;101(2):395-415. doi: 10.1016/j.mcna.2016.09.010
8. Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-17. doi: 10.2215/CJN.00620117
9. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-7. doi: 10.1093/ckj/sfz040
10. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4-21. doi: 10.1111/1744-9987.12763
11. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;38:817-24. doi: 10.1016/S0140-6736(17)30062-4
12. Plautz WE, Raval JS, Dyer MR, et al. ADAMTS13: origins, applications, and prospects. Transfusion. 2018;58(10):2453-62. doi: 10.1111/trf.14804
13. Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol. 2019;10:337. doi: 10.3389/fimmu.2019.00337
14. Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-86. doi: 10.1053/j.ackd.2019.08.012
15. Chaturvedi S, Brodsky RA, McCrae KR. Complement in the Pathophysiology of the Antiphospholipid Syndrome. Front Immunol. 2019;10:449. doi: 10.3389/fimmu.2019.00449
16. Zanatta E, Polito P, Favaro M, et al. Therapy of scleroderma renal crisis: State of the art. Autoimmun Rev. 2018;17(9):882-9. doi: 10.1016/
j.autrev.2018.03.012
17. Allanore Y, Distler O, Matucci-Cerinic M, Denton CP. Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis Rheumatol. 2018;70(2):162-70. doi: 10.1002/art.40377
18. Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-47. doi: 10.1038/nrrheum.2017.125
19. Goldberg BS, Ackerman ME. Antibody-mediated complement activation in pathology and protection. Immunol Cell Biol. 2020 Mar 6. doi: 10.1111/imcb.12324
20. Dijkstra DJ, Joeloemsingh JV, Bajema IM, Trouw LA. Complement activation and regulation in rheumatic disease. Semin Immunol. 2019;45:101339. doi: 10.1016/j.smim.2019.101339
21. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune
Disease. Front Immunol. 2019;10:672. doi: 10.3389/fimmu.2019.
00672
22. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
23. Насонов Е.Л. Системная красная волчанка. В кн.: Российские клинические рекомендации. 2017. М.: ГЭОТАР-Медиа, 2017; с. 113-41 [Nasonov EL. Systemic lupus erythematosus. In: Russian Kliscientific recommendations. 2017. Moscow: GEOTAR-Media, 2017; p. 113-41 (In Russ.)].
24. Couture P, Hie M, Pineton de Chambrun M, et al. FRI0302 Systemic lupus erythematosus-associated thrombotic microangiopathies in 60 patients: clinical features, prognosis and treatment in a french multicentric cohort. Ann Rheum Dis. 2018;77:688-9.
25. Yue C, Su J, Gao R, et al. Characteristics and Outcomes of Patients with Systemic Lupus Erythematosus-associated Thrombotic Microangiopathy, and Their Acquired ADAMTS13 Inhibitor Profiles. J Rheumatol. 2018;45(11):1549-56. doi: 10.3899/jrheum.170811
26. Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005
27. Hess DC, Sethi K, Awad E. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus and antiphospholipid antibodies: effective treatment with plasma exchange and immunosuppression. J Rheumatol. 1992;19:1474-8. PMid: 1433020.
28. Durand JM, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome. J Rheumatol. 1991;18:1916-8. PMid: 1795331.
29. Tulai IM, Penciu OM, Raut R, Rudinskaya A. Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. Tex Heart Inst J. 2019;46(1):48-52. doi: 10.14503/THIJ-17-6472
30. Sciascia S, Cuadrado MJ, Khamashta M, et al. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10:279-89.
doi: 10.1038/nrneph.2014.38
31. Tsuchimoto A, Matsukuma Y, Ueki K, et al. Thrombotic microangiopathy associated with anticardiolipin antibody in a kidney transplant recipient with polycythemia. CEN Case Rep. 2019;8(1):1-7.
doi: 10.1007/s13730-018-0354-x
32. Zhou XJ, Chen M, Wang SX, et al. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report. Lupus. 2017;26(7):777-82.
doi: 10.1177/0961203316682098
33. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-6. doi: 10.1136/ard.2003.007245
34. Asherson RA, Pierangel SS, Cervera R. Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis. 2007;66:429-33.
doi: 10.1136/ard.2006.067033
35. Myakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306.
doi: 10.1111/j.1538-7836.2006.01753.x
36. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
doi: 10.1002/art.10187
37. Решетняк Т.М., Алекберова З.С., Александрова Е.Н. и др. Клинические аспекты антифосфолипидного синдрома. Вестн. РАМН. 2003;7:31-4 [Reshetnyak TM, Alekberova ZS, Alexandrova EN, et al. Clinic-clinical aspects of antiphospholipid syndrome. Vestn. RAMS. 2003;7:31-4 (In Russ.)].
38. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004 [Nasonov EL. Antifosfolipidnyi sindrom. Moscow: Litterra, 2004 (In Russ.)].
39. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018;378(21):2010-21. doi: 10.1056/NEJMra1705454
40. Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv. 2018;2(16):2090-4. doi: 10.1182/bloodadvances.2018019596
41. Ding Y, Tan Y, Qu Z, Yu F. Renal microvascular lesions in lupus nephritis. Ren Fail. 2019;42(1):19-29. doi: 10.1080/0886022X.2019.1702057
42. Ono M, Ohashi N, Namikawa A, et al. A Rare Case of Lupus Nephritis Presenting as Thrombotic Microangiopathy with Diffuse Pseudotubulization Possibly Caused by Atypical Hemolytic Uremic Syndrome. Intern Med. 2018;57(11):1617-23. doi: 10.2169/internalmedicine.0228-17
43. Yu F, Haas M, Glassock R, Zhao MH. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13:483-95. doi:
10.1038/nrneph.2017.85
44. Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013;15(1):R12. doi: 10.1186/ar4142
45. Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005
46. Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007
47. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213
48. Насонов Е.Л., Бекетова Т.В., Ананьева Л.П. и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov ЕL, Beketova TV, Ananyeva LP, et al. Prospects for anti-b-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (In Russ.)]. doi: 10.14412/1995-4484-2019-3-40
49. Berman H, Rodríguez-Pintó I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004
50. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793
51. Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012
52. Diószegi Á, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018;27(9):1552-8. doi: 10.1177/0961203318768890
53. Bhat SP, Rahman SZ. Rituximab treatment in new and refractory thrombotic thrombocytopenic purpura (TTP) patients: a review. IJMSCR. 2016;2:1-6.
54. Sun L, Mack J, Li A, et al. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512-8. doi: 10.1182/bloodadvances
55. Coppo P. Cuker A, George JN. Thrombotic thrombocytopenic purputa: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2019;3:26-37. doi: 10.1002/rth2.12160
56. Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet. 2019;58(7):859-74. doi: 10.1007/s40262-019-00742-8
57. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25-40. doi: 10.3904/kjim.201
58. Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648. doi: 10.1016/j.jns.2019.11
59. Patel A, Lynch F, Shepherd SA. Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit. Curr Treat Options Neurol. 2020;22(3):7. doi: 10.1007/s11940-020-0616-8
60. Tinti MG, Carnevale V, Inglese M, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019;19(3):281-8. doi: 10.1007/s10238-019-00565-8
61. De Holanda MI, Pôrto LC, Wagner T, et al. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol. 2017;36(12):2859-67. doi: 10.1007/s10067-017-3823-2
62. Raufi AG, Scott S, Darwish O, et al. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep. 2016;8(3):6625. eCollection 2016 Sep 28.
63. El-Husseini A, Hannan S, Awad A, et al. Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis. 2014;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031
64. Pickering MC, Ismajli M, Condon MB, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford). 2015;54(12):2286-8. doi: 10.1093/rheumatology/kev307
65. Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719-23. doi: 10.1002/art.34440
66. Appenzeller S, Souza FH, Wagner Silva de Souza A, et al. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517-23. doi: 10.1016/j.semarthrit.2011.05.007
67. Muller-Calleja N, Ritter S, Hollerbach A, et al. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv. 2018;2:979-86. doi: 10.1182/bloodadvances.2018017095
68. Strakhan M, Hurtado-Sbordoni M, Galeas N, et al. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371. doi: 10.1155/2014/704371
69. Wig S, Chan M, Thachil J, et al. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382-4. doi: 10.1093/rheumatology/kev371
70. Gustavsen A, Skattum L, Bergseth G, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report. Medicine. 2017;96:e6338. doi: 10.1097/MD.0000000000006338
71. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost. 2016;14:675-84. doi: 10.1111/jth.13257
72. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143. doi: 10.1097/MD.0000000000000143
73. Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337-9. doi: 10.1093/rheumatology/kew040
74. Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome – a case report and literature review. Rheumatology. 2018;57:2055-7. doi: 10.1093/rheumatology/key2
75. Geethakumari PR, Mille P, Gulati R, Nagalla S. Complement inhibition with eculizumab for thrombotic microangiopathy rescues a living-donor kidney transplant in a patient with antiphospholipid antibody syndrome. Transfus Apher Sci. 2017;56(3):400-3. doi: 10.1016/j.transci.2017.02.007
76. Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome. Clin Rheumatol. 2015;21(6):311-3. doi: 10.1097/RHU.0000000000000290
77. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14(2):459-65. doi: 10.1111/ajt.12540
78. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744-5. doi: 10.1056/NEJMc0910965
79. Bakhtar O, Thajudeen B, Braunhut BL, et al. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. Transplantation. 2014;98(3):e17-8. doi: 10.1097/TP.0000000000000267
80. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013;13(8):2179-85. doi: 10.1111/ajt.12319
81. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x
82. Olson SR, Lu E, Sulpizio E, et al. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies. Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033
83. Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol. 2019;114:341-52. doi: 10.1016/j.molimm.2019.07.030
84. Thurman JM, Yapa R. Complement Therapeutics in Autoimmune Disease. Front Immunol. 2019 Apr 3;10:672. doi: 10.3389/fimmu.2019.00672
85. Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS One 11:e0164646. doi: 10.1371/journal.pone.0164646
86. Jayne DRW, Bruchfeld AN, Harper L, et al; CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017;28(9):2756-67. doi: 10.1681/ASN.2016111179
87. Callewaert F, Roodt J, Ulrichts H, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012;120:3603-10. doi: 10.1182/blood-2012-04-420943
88. Hanlon A, Metjian A. Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020;11:2040620720902904. doi: 10.1177/2040620720902904
Авторы
Е.Л. Насонов1,2, Т.М. Решетняк1,3, З.С. Алекберова1
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия;
2 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
________________________________________________
1 Nasonova Research Institute of Rheumatology, Moscow, Russia;
2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.